StockData
Rallybio Corp logo

Rallybio Corp (RLYB) company profile

RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)

Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –

About Rallybio

Pharmaceutical Preparations, SIC 2834

Rallybio Corporation is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapeutic candidates for individuals affected by severe and rare diseases. The company's pipeline centers on candidate treatments for complement dysregulation and hematological disorders. Its lead investigational asset is RLYB116, a complement component 5 inhibitor designed for subcutaneous administration to treat rare complement-mediated conditions. Rallybio is also developing RLYB332, a preclinical matriptase-2 antibody targeting diseases characterized by ineffective erythropoiesis and iron overload. The business further engages in research collaborations with industry partners to discover antibody-based therapies for rare metabolic and other disorders.

The company conducts clinical and preclinical research activities across various therapeutic development programs. Its intellectual property portfolio spans granted patents and pending patent applications across the United States, Europe, Japan, Canada, Australia, and numerous other international jurisdictions. The provided text does not identify the location of Rallybio's corporate headquarters.

Summary of the business section of Rallybio's latest annual report, written by StockData.

Company profile

Company

Legal name
Rallybio Corp
Headquarters
New Haven, CT
Address
234 Church Street, Suite 1020 06510
Phone
(203) 859-3820
Employees
14, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Hartford, Connecticut

Stock & identifiers

Ticker
RLYB
Exchange
Nasdaq
IPO date
Jul 30, 2021
Shares outstanding
5M, Oct 20, 2026
Public float
$10.60M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-8 reverse, Feb 6, 2026; 25-for-4, Nov 10, 2021
SEC CIK
1739410
CUSIP
75120L209
ISIN
US75120L2097
FIGI
BBG011PFKF54
Share class FIGI
BBG011PFKG07
LEI
254900OR8EZO4FXWJY12
EIN
85-1083789

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Stephen UdenChief Executive Officer, Director148,864
Jonathan I. LieberChief Financial Officer44,139
Steven RyderChief Medical Officer192,370
Ronald HuntDirector2,330,728
Martin MackayDirector561,549
Christine A. NashDirector3,562
Wendy ChungDirector5,624
Helen M. BoudreauDirector8,604
Paula SoteropoulosDirector6,544
Robert Lorne HopfnerDirector2,282,231
Hui LiuDirector3,562

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 30, 2021
Offer price
$13.00
Securities offered
6,200,000
Gross proceeds
$80.60M
Exchange
Nasdaq
First trading day
Jul 29, 2021
First-day close
$14.10+8.5%
Lock-up ends (est.)
Jan 25, 2022

“The initial public offering price is $13.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 14 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?